Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY24 results · Apr–Jun 2023
Bliss GVS Pharma reported revenue from operations of ₹159.52 crore (down 15.4% from Q1 FY23) and net profit of ₹14.37 crore (down 47.7% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 159.52 | 188.66 | −15.4% | 184.78 | −13.7% |
| Other income | 5.11 | 7.01 | −27.1% | 2.98 | +71.7% |
| Total income | 164.63 | 195.67 | −15.9% | 187.76 | −12.3% |
| Profit before tax | 21.65 | 39.20 | −44.8% | (0.75) | Turned profit |
| Net profit for the period | 14.37 | 27.48 | −47.7% | 3.46 | +314.9% |
| Attributable to shareholders of the company | 14.69 | 25.72 | −42.9% | 3.34 | +339.2% |
| EPS, basic (₹) | 1.41 | 2.48 | −43.1% | 0.34 | +314.7% |
| Net margin (%) | 9.0 | 14.6 | 1.9 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 108.99 | 147.28 | −26.0% | 143.42 | −24.0% |
| Other income | 6.53 | 18.63 | −65.0% | 6.48 | +0.7% |
| Total income | 115.52 | 165.91 | −30.4% | 149.90 | −22.9% |
| Profit before tax | 10.90 | 32.07 | −66.0% | 8.44 | +29.1% |
| Net profit for the period | 7.50 | 24.65 | −69.6% | 6.11 | +22.7% |
| EPS, basic (₹) | 0.72 | 2.38 | −69.7% | 0.60 | +20.0% |
| Net margin (%) | 6.9 | 16.7 | 4.3 |
Consolidated
- Filed with BSE
- 01 Aug 2023, 19:05 IST
- Board meeting
- 01 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Aug 2023, 19:05 IST
- Board meeting
- 01 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE